


Searching News Database: oritavancin
HSMN NewsFeed - 5 Jun 2014
ORBACTIV(TM) (Oritavancin) Phase 3 Trial Results Published in New England Journal of Medicine
ORBACTIV(TM) (Oritavancin) Phase 3 Trial Results Published in New England Journal of Medicine
HSMN NewsFeed - 20 May 2014
Spero Therapeutics Appoints Thomas Parr, Ph.D. as Chief Scientific Officer
Spero Therapeutics Appoints Thomas Parr, Ph.D. as Chief Scientific Officer
HSMN NewsFeed - 13 May 2009
The Medicines Company Discontinues Phase 3 CHAMPION Clinical Trial Program of Cangrelor
The Medicines Company Discontinues Phase 3 CHAMPION Clinical Trial Program of Cangrelor
HSMN NewsFeed - 26 Feb 2009
The Medicines Company Completes Acquisition of Targanta Therapeutics Corporation
The Medicines Company Completes Acquisition of Targanta Therapeutics Corporation
Additional items found! 6
Members Archive contains
6 additional stories matching:
oritavancin
(Password required)
oritavancin
(Password required)
